The University of Oxford has launched the first study to assess the safety and immune responses of its Covid-19 vaccine in children and young adults with the first vaccinations expected during this month.
This trial will assess if children and young adults aged 6-17 years develop a good immune response with the ChAdOx1 nCoV-19 vaccine.
“While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination,” Andrew Pollard, Professor, and Chief Investigator on the Oxford vaccine trial, said in a statement.
“These new trials will extend our understanding of control of SARS-CoV2 to younger age groups.”
The study builds on previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in adults. This new trial, a…